Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Pat W WhitworthPeter D BeitschJames V PellicanePaul L BaronLaura A LeeCarrie L DulMary K MurrayMark A GittlemanRaye J BudwayRakhshanda Layeequr RahmanPond R KelemenWilliam C DooleyDavid T RockKenneth H CowanBeth-Ann LesnikoskiJulie L BaroneAndrew Y AshikariBeth B DupreeShiyu WangAndrea R MenicucciErin B YoderChristine FinnKate CorcoranLisa E BlumencranzM William Audehnull nullPublished in: JCO precision oncology (2022)
Significant differences in chemosensitivity and 5-year outcome suggest patients with ER+/Basal molecular subtype may benefit from neoadjuvant regimens optimized for patients with TNBC/Basal tumors compared with patients with ER+/Luminal subtype. These data highlight the importance of identifying this subset of patients to improve treatment planning and long-term survival.
Keyphrases
- estrogen receptor
- neoadjuvant chemotherapy
- epidermal growth factor receptor
- locally advanced
- lymph node
- end stage renal disease
- tyrosine kinase
- rectal cancer
- ejection fraction
- endothelial cells
- advanced non small cell lung cancer
- newly diagnosed
- prognostic factors
- sentinel lymph node
- genome wide
- squamous cell carcinoma
- patient reported outcomes
- single molecule
- deep learning
- genome wide identification
- genome wide analysis